1792181-33-9
1792181-33-9
Chemical Structure
Vunakizumab
Synonym(s): Anti-Human IL17A Recombinant Antibody; SHR-1314
- CAS No.: 1792181-33-9
- Formula:N/A
- Molecular Weight:(146.38 kDa)
IUPAC Name: 2-(3-((tert-butyldimethylsilyl)oxy)-3-methylcyclobutyl)-5-(tributylstannyl)-4-(trifluoromethyl)thiazole
SMILES: [Vunakizumab]
Biological Activity: Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGκ monoclonal antibody and an Interleukin-17A (IL-17A) inhibitor. Vunakizumab binds to IL-17A to inhibit downstream cytokines and block inflammatory signaling. Vunakizumab can be used for the research of chronic plaque psoriasis and ankylosing spondylitis[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Vunakizumab | 95.00% | Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGκ monoclonal antibody and an Interleukin-17A (IL-17A) inhibitor. Vunakizumab binds to IL-17A to inhibit downstream cytokines and block inflammatory signaling. Vunakizumab can be used for the research of chronic plaque psoriasis and ankylosing spondylitis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Liu SH, et al. Recent Advances of Second-Line Targeted Biopharmaceutical Therapies in Thyroid Associated Ophthalmopathy. Adv. Therap. 2024 Jul 05;7(9):2400137.
- [2]. Zhang C, et al. A multicenter, randomized, double-blinded, placebo-controlled, dose-ranging study evaluating the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis. J Am Acad Dermatol.
